CLINICAL TRIALS PROFILE FOR LUMASON
✉ Email this page to a colleague
All Clinical Trials for Lumason
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02282163 ↗ | Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography | Terminated | Bracco Diagnostics, Inc | Phase 3 | 2015-10-01 | Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults. |
| NCT02522481 ↗ | Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141 | Completed | Bracco Diagnostics, Inc | Phase 3 | 2015-09-24 | The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography. |
| NCT02552238 ↗ | Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142 | Completed | Bracco Diagnostics, Inc | Phase 3 | 2015-10-12 | The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography. |
| NCT02911714 ↗ | Contrast-Enhanced Ultrasound for Kidney Transplant | Recruiting | American Heart Association | Phase 1 | 2018-02-21 | Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lumason
Condition Name
Clinical Trial Locations for Lumason
Trials by Country
Clinical Trial Progress for Lumason
Clinical Trial Phase
Clinical Trial Sponsors for Lumason
Sponsor Name
